🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "major milestone" in the effort against superbug strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are on the rise globally, with figures suggesting more than 82 million instances annually. Notably increased rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the context of growing infection rates, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This disease can lead to major issues, including infertility. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone represents a significant shift in the management of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Results and Global Access

According to findings detailed in a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which uses an injection and a pill. The research included nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the authority to make available and distribute the drug in numerous regions with limited resources.

Doctors directly involved have voiced hope. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for public health efforts. This is deemed crucial to lessen the impact of the infection for patients and to halt the transmission of extremely resistant gonorrhoea around the world.